INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ChemoCentryx, Inc. and Encourages Investors with Losses to Contact the Firm

b'The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ChemoCentryx, Inc. (\xe2\x80\x9cChemoCentryx\xe2\x80\x9d or \xe2\x80\x9cthe Company\xe2\x80\x9d) (NASDAQ: CCXI ) for violations of the securities laws.\nThe investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Information
Retrieved on: 
Tuesday, May 4, 2021 - 11:00pm
Stock Symbol: 
Content
Key Points: 
  • b'The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ChemoCentryx, Inc. (\xe2\x80\x9cChemoCentryx\xe2\x80\x9d or \xe2\x80\x9cthe Company\xe2\x80\x9d) (NASDAQ: CCXI ) for violations of the securities laws.\nThe investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • The FDA released a \xe2\x80\x9cBriefing Document\xe2\x80\x9d on May 4, 2021, concerning ChemoCentryx\'s drug candidate avacopan.
  • The FDA document notes that the agency\xe2\x80\x99s review team "has identified several areas of concern, raising uncertainties about the interpretability of the data" found in the Company\xe2\x80\x99s application, and also holds concerns about "the clinical meaningfulness of these results."
  • You can also reach us through the firm\'s website at www.schallfirm.com , or by email at brian@schallfirm.com .\nThe class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney.


The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ChemoCentryx, Inc. (“ChemoCentryx” or “the Company”) (NASDAQ: CCXI) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The FDA released a “Briefing Document” on May 4, 2021, concerning ChemoCentryx's drug candidate avacopan. The FDA document notes that the agency’s review team "has identified several areas of concern, raising uncertainties about the interpretability of the data" found in the Company’s application, and also holds concerns about "the clinical meaningfulness of these results." Based on this news, shares of ChemoCentryx plunged by more than 45% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.